ProMIS Neurosciences (PMN) Investor presentation summary

Strategic focus and technology

• Pipeline targets underlying causes of neurodegenerative diseases by focusing on toxic misfolded proteins.

• EpiSelect computational platform enables generation of antibodies highly selective for toxic protein conformations, differentiating from conventional approaches.

• Unique selectivity aims to address unmet needs for safer, more effective therapies in neurodegeneration.

Pipeline and clinical development

• Lead candidate PMN310 targets toxic amyloid-beta oligomers in Alzheimer's, with FDA Fast Track designation.

• Additional candidates address TDP-43 (ALS, FTD), alpha-synuclein (PD, MSA, DLB), and vaccines for prevention and proteinopathies.

• Robust Phase 1b trial in early Alzheimer's fully enrolled (n=144), with interim blinded biomarker and safety data expected early Q3 2026 and topline results in Q1 2027.

Clinical and market positioning

• PMN310 demonstrated high selectivity for toxic oligomers, avoiding plaque binding and associated ARIA risks seen with other therapies.

• Phase 1a trial showed PMN310 was well-tolerated, achieved high CSF target saturation, and supports monthly dosing.

• Market potential for PMN310 in early Alzheimer's estimated at over $10 billion in peak sales.

• Standard-of-care therapies show limited efficacy and significant ARIA safety concerns, yet still achieve multi-billion dollar sales.